Garheng Kong joined Sofinnova Ventures in 2010 as managing general partner. Sofinnova Ventures applies capital and expertise to guide life science companies to successful exits. The firm's investment team of MDs and PhDs has significant scientific, operational, and strategic experience, and the team specializes in financing clinical stage products.
Garheng has served as chairman and director on the boards of numerous companies and operated as interim CEO for two venture-backed companies. For the 10 years prior, he was a general partner at Intersouth Partners. Some of his roles have included serving as the founding investor of Cellective Therapeutics (acquired by AstraZeneca), chairman of Serenex (acquired by Pfizer), chairman of Novamin Technologies (acquired by GlaxoSmithKline), chairman of Viamet Pharmaceuticals, chairman of Cempra Pharmaceuticals (NASDAQ: CEMP) and lead investor for Alimera Sciences (NASDAQ: ALIM).
Garheng completed the MD/PhD (biomedical engineering) program in 1999 at Duke and worked closely with Chancellor Emeritus Ralph Snyderman, MD, on one of his rotations. He has been a member of the FSB Entrepreneur Affiliates and the Entrepreneurship and Innovation Task Force. He has also served on the Duke University Medical Center Institutional Review Board and as faculty at the Duke Fuqua School of Business as a senior scholar. He has been involved in commercializing early-stage technology with the Duke University Office of Science and Technology.
Kong holds a BS in chemical engineering and a BS in biological sciences from Stanford University. Prior to his career in venture capital, he worked as a clinical scientist at Glaxo Wellcome and a consultant at McKinsey & Company. His father, Ying-Suen Kong, MD, from Taiwan; sister, Garyun Blackmon, MD’01, H’06; and wife, Melissa Kong, MD’04 H’11, are all practicing physicians.